Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/57607
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bakay, O.S.K. | - |
dc.contributor.author | Kacar, N. | - |
dc.contributor.author | Gul, B. | - |
dc.contributor.author | Goksin, S. | - |
dc.contributor.author | Gural, Y. | - |
dc.date.accessioned | 2024-07-28T17:17:39Z | - |
dc.date.available | 2024-07-28T17:17:39Z | - |
dc.date.issued | 2024 | - |
dc.identifier.issn | 1539-6304 | - |
dc.identifier.uri | https://doi.org/10.2500/aap.2024.45.240041 | - |
dc.identifier.uri | https://hdl.handle.net/11499/57607 | - |
dc.description.abstract | Background: Chronic spontaneous urticaria (CSU) is a common disease with complex pathogenesis. Patients' clinical characteristics and responses to treatment vary. Objective: We aimed to investigate the role of data obtained from routinely recommended tests in predicting the response to omalizumab, the only biologic agent approved for treatment, and in defining the clinical characteristics of the patients. Methods: A retrospective study of patients who started omalizumab treatment for CSU between 2015 and 2022 at the Department of Dermatology, Pamukkale University, was conducted. Response criteria were based on the urticaria control test, and patients with a urticaria control test score <12 at 6 months were considered treatment non-responders. Eosinophil and basophil counts, neutrophil-lymphocyte ratio (NLR), systemic immune inflammation index (SII), systemic inflammation response index (SIRI), and total immunoglobulin E (IgE) levels of the patients were evaluated before treatment and at the sixth month of treatment. Results: A total of 23.1% of the patients were unresponsive to omalizumab. The response rate to the omalizumab treatment of the patients with a total IgE level ≤ 30 IU/L (n = 4 [5.7%]) was significantly lower than patients with total IgE level > 30 IU/L (n = 66 [94.3%]) (p = 0.015). The mean ± standard deviation SIRI levels were significantly higher in non-responders versus responders (1.53 ± 1.03 versus 1.15 ± 7.76; p = 0.026). Eosinophil counts positively correlated with basophil counts (r = 587; p < 0.001) and IgE levels (r = 0.290; p = 0.005) but a negative correlation was found with levels of NLR (r = -0.475; p < 0.001), SIRI (r = -0.259; p = 0.013), and SII (r = -0.285; p = 0.006). NLR levels were lower in CSU patients with atopy, than in those without atopy (1.9 ± 0.9 vs 2.9 ± 2.1, p = 0.022). Conclusion: We suggest that eosinopenia and high NLR levels are linked to autoimmune CSU. Predicting a poor response to omalizumab seems possible with total IgE levels < 30 IU/L and high SIRI levels. | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | Allergy and asthma proceedings | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | antiallergic agent | en_US |
dc.subject | immunoglobulin E | en_US |
dc.subject | omalizumab | en_US |
dc.subject | adult | en_US |
dc.subject | aged | en_US |
dc.subject | blood | en_US |
dc.subject | chronic urticaria | en_US |
dc.subject | drug therapy | en_US |
dc.subject | eosinophil | en_US |
dc.subject | female | en_US |
dc.subject | human | en_US |
dc.subject | immunology | en_US |
dc.subject | leukocyte count | en_US |
dc.subject | male | en_US |
dc.subject | middle aged | en_US |
dc.subject | retrospective study | en_US |
dc.subject | treatment outcome | en_US |
dc.subject | young adult | en_US |
dc.subject | Adult | en_US |
dc.subject | Aged | en_US |
dc.subject | Anti-Allergic Agents | en_US |
dc.subject | Chronic Urticaria | en_US |
dc.subject | Eosinophils | en_US |
dc.subject | Female | en_US |
dc.subject | Humans | en_US |
dc.subject | Immunoglobulin E | en_US |
dc.subject | Leukocyte Count | en_US |
dc.subject | Male | en_US |
dc.subject | Middle Aged | en_US |
dc.subject | Omalizumab | en_US |
dc.subject | Retrospective Studies | en_US |
dc.subject | Treatment Outcome | en_US |
dc.subject | Young Adult | en_US |
dc.title | What can be learned from real-world data about chronic spontaneous urticaria? | en_US |
dc.type | Article | en_US |
dc.identifier.volume | 45 | en_US |
dc.identifier.issue | 4 | en_US |
dc.identifier.startpage | 255 | en_US |
dc.identifier.endpage | 261 | en_US |
dc.department | Pamukkale University | en_US |
dc.identifier.doi | 10.2500/aap.2024.45.240041 | - |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.authorscopusid | 57797495800 | - |
dc.authorscopusid | 15750610300 | - |
dc.authorscopusid | 59217389900 | - |
dc.authorscopusid | 57194194375 | - |
dc.authorscopusid | 57216618247 | - |
dc.identifier.pmid | 38982597 | en_US |
dc.identifier.scopus | 2-s2.0-85198471199 | en_US |
dc.identifier.wos | WOS:001267352700012 | en_US |
dc.institutionauthor | … | - |
item.languageiso639-1 | en | - |
item.fulltext | No Fulltext | - |
item.openairetype | Article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | none | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
Appears in Collections: | Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
CORE Recommender
SCOPUSTM
Citations
1
checked on Oct 13, 2024
WEB OF SCIENCETM
Citations
1
checked on Oct 31, 2024
Page view(s)
20
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.